Studying the nuclear/cytoplasmic localization of proteins following treatment with CRM1 inhibitors, can potentially lead to the identification of activated pathways that may be targeted with small molecule inhibitors, either novel or repurposed such as what happened with Zafirlukast, to proteins involved in these pathways that could be then used in cancer treatments. The gene discussed is XPO1; the disease is cancer.